Skip to main content

Table 1 Baseline demographic, anamnestiс, clinical and laboratory characteristics of JIA severity in patients enrolled in the study

From: Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial

Parameter

ETA + MTX (n = 35)

Placebo + MTX (n = 33)

p

Demographic characteristics

 Sex:

0.471

  female, n (%)

22 (64.71%)

25 (75.76%)

  male, n (%)

12 (35.29%)

8 (24.24%)

Age at enrolment, years; median (IQR range)

9.8 (5.82–12.94)

6.62 (4.1–13.26)

0.11

Disease duration (starting from the onset symptoms) to baseline years; median (IQR range)

0.81 (0.29–1.68)

0.74 (0.32–3.48)

0.632

Age of onset of specific complaints years; median (IQR range)

7.2 (4.38–10.82)

4.7 (2.4–9.44)

0.032

Age at diagnosis years; median (IQR range)

9.16 (5.4–12.05)

4.86 (2.49–11.37)

0.035

Disease duration until diagnosis, years

2.5 (1–9)

3 (2–16)

0.38

JIA category

 Seronegative Polyarthritis, n (%)

21 (60%)

16 (48%)

0.47

 Seropositive Polyarthritis, n (%)

1 (2.9%)

0

1.0

 Extended Oligoarthritis, n (%)

8 (23%)

12 (36%)

0.29

 Polyarticular enthesitis associated arthritis, n (%)

5 (14.3%)

3 (9%)

0.71

 Unclassified polyarticular JIA, n (%)

0

2 (6%)

0.23

Prior treatment

 Conventional NSAIDs, n (%)

31 (88.57%)

27 (81.82%)

0.507

 COX-2 inhibitors, n (%)

11 (32.35%)

13 (39.39%)

0.729

 Sulfasalazine, n (%)

6 (17.14%)

9 (27.27%)

0.475

 Leflunomide, n (%)

1 (2.86%)

0 (0%)

> 0.999

 Oral GCs, n (%)

1 (2.86%)

2 (6.06%)

0.608

 Other GCs, n (%)

11 (31.43%)

8 (24.24%)

0.697

Clinical and laboratory characteristics

 Swollen joint count, median (IQR range)

6 (4–9)

4 (2–7)

0.018

 Tender joint count, median (IQR range)

6 (4.5–12.5)

6 (4–12)

0.349

 Number of joints with LOM, median (IQR range)

6 (4.5–10.5)

6 (3–14)

0.521

 Number of active joints, median (IQR range)

7 (6–11.5)

7 (4–12)

0.191

 Haemoglobin, median (IQR range)

12 (11.45–12.8)

12 (11.4–12.5)

0.726

 ESR, median (IQR range)

12 (2–20)

12 (8–23)

0.301

 CRP, median (IQR range)

3.5 (1–13.45)

0.7 (0–9)

0.003

 JADAS-71, median (IQR range)

24 (18–34)

19 (17–24.3)

0.025

 CHAQ, median (IQR range)

1.5 (0.75–1.75)

1 (0.5–1.5)

0.057

 Physician’s assessment of disease activity using VAS, median (IQR range)

8 (6–9)

6 (5–7)

0.014

 Patient’s assessment of well-being using VAS

8 (5–9)

7 (5–8)

0.114

 Patient’s assessment of disease activity using VAS, median (IQR range)

7.5 (5–8)

7 (5–8)

0.353

  1. P values are based on the Mann-Whitney U-test (for continuous data) and on Pearson’s χ2 test (for categorical data)